
Jazz Pharmaceuticals Gets EU Approval for Ziihera to Treat Advanced HER2-Positive Biliary Tract Cancer
Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted conditional marketing authorization for Ziihera® (zanidatamab), a dual HER2-targeted bispecific antibody, as monotherapy for adults with unresectable locally advanced or …